ScholarIQanswers from OpenAlex & ORCID
Björn Dahlöf
ResearcherPublications, citations & collaboration network
Björn Dahlöf is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Björn Dahlöf have?
ScholarIQindexed works
Björn Dahlöf has 249 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Björn Dahlöf have?
ScholarIQcitation count
Björn Dahlöf has 25,591 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Björn Dahlöf?
ScholarIQh-index
Björn Dahlöf has an h-index of 57 in OpenAlex.
What is the i10-index of Björn Dahlöf?
ScholarIQi10-index
Björn Dahlöf has an i10-index of 141 in OpenAlex.
What is the ORCID of Björn Dahlöf?
ScholarIQorcid
The ORCID for Björn Dahlöf is on the source record.
What is the OpenAlex record for Björn Dahlöf?
ScholarIQopenalex
The OpenAlex for Björn Dahlöf is on the source record.
What are the most-cited papers on Björn Dahlöf?
ScholarIQmost cited works
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson, Alberto Zanchetti, S. George Carruthers, Björn Dahlöf, Dag Elmfeldt, Stevo Julius, Joël Ménard, K. H. Rahn, Hans Wedel, S. Westerling
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Björn Dahlöf, Peter Sever, Neil R Poulter, Hans Wedel, DG Beevers, Mark J. Caulfield, Rory Collins, Sverre E. Kjeldsen, Arni Kristinsson, Gordon T. McInnes, Jesper Mehlsen, Markku S. Nieminen, Eoin OʼBrien, Jan Östergren
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Björn Dahlöf, L. Hansson, Lars Lindholm, Bengt Scherstén, Tord Ekbom, P-O Wester
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lars Lindholm, Hans Ibsen, Björn Dahlöf, Richard B. Devereux, Gareth Beevers, Ulf dé Fairé, Frej Fyhrquist, Stevo Julius, Sverre E. Kjeldsen, Krister Kristiansson, Ole Lederballe‐Pedersen, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Peter Aurup, Jonathan M. Edelman, Steven Snapinn
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
Lennart Hansson, Lars Lindholm, Tord Ekbom, Björn Dahlöf, Jan Lanke, Bengt Scherstén, P-O Wester, Thomas Hedner, Ulf dé Fairé